CN102702116B - 4-(3-chloro-4-methoxylanilino)-6-(3-amidophenyl)quinazoline compound or pharmaceutically-acceptable salt thereof and preparation methods and applications thereof - Google Patents

4-(3-chloro-4-methoxylanilino)-6-(3-amidophenyl)quinazoline compound or pharmaceutically-acceptable salt thereof and preparation methods and applications thereof Download PDF

Info

Publication number
CN102702116B
CN102702116B CN201210194142.7A CN201210194142A CN102702116B CN 102702116 B CN102702116 B CN 102702116B CN 201210194142 A CN201210194142 A CN 201210194142A CN 102702116 B CN102702116 B CN 102702116B
Authority
CN
China
Prior art keywords
chloro
quinazoline
methoxy anilino
methoxy
anilino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201210194142.7A
Other languages
Chinese (zh)
Other versions
CN102702116A (en
Inventor
刘芳
周博
何经纬
黄唯燕
刘伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
South China University of Technology SCUT
Original Assignee
South China University of Technology SCUT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South China University of Technology SCUT filed Critical South China University of Technology SCUT
Priority to CN201210194142.7A priority Critical patent/CN102702116B/en
Publication of CN102702116A publication Critical patent/CN102702116A/en
Application granted granted Critical
Publication of CN102702116B publication Critical patent/CN102702116B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention discloses a 4-(3-chloro-4-methoxylanilino)-6-(3-amidophenyl)quinazoline compound shown as a structure formula (I). In the structure formula (I), R is any one of -H, -COCH3, -COCF3, -COCH=CHCOOH, -COCH2Cl, -COCCl3, -COCH=CH2, -COC(CH3)3, -COCH2CH3 and -COHBrCH3. The invention further relates to a preparation method of the compound, a pharmaceutically-acceptable salt of the compound, and applications of the compound and the pharmaceutically-acceptable salt thereof to preparation of an antitumor medicament.

Description

4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds or its pharmacy acceptable salt and preparation method and application
Technical field
The present invention relates to chemical synthetic drug technical field, be specifically related to an organic micromolecule 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds or its pharmacy acceptable salt, their preparation method and preparing the application in antitumor drug.
Background technology
Cancer is one of principal disease of serious harm human health, and the number dying from cancer is every year cumulative year after year trend.Cancer has become the second largest killer of the mankind being only second to cardiovascular diseases.Capture cancer is the research topic attracted attention in the world always.Treatment at present for cancer mainly contains the methods such as operative treatment, radiotherapy, chemotherapy, and wherein chemotherapy accounts for very important status in the treatment of cancer.
Traditional cancer therapy drug mainly cytotoxic drug, this kind of cancer therapy drug mainly acts on the key ingredient such as DNA, RNA and tubulin of cell, and great majority are nonselective, while killing and wounding cancer cells, also can kill and wound the normal cell of body, there is the shortcoming such as poor selectivity, strong, the easy generation resistance of toxic side effect being difficult to avoid.
Significantly not enough in order to overcome these of conventional anti-cancer medicines, the mankind are very active for the research and development of the organic molecule PTS with target feature.Organic molecule PTS utilizes the targeting of its molecule or structural points, reaches the object of the selectivity significantly improving cancer therapy drug, the toxicity reducing cancer therapy drug.
In recent years, along with Gefitinib (Gefitinib), Tarceva (Erlotinib), lapatinibditosylate (Lapatinib), PD 183805 and PD 153035 etc., these contain the listing successively of the PTS of amido quinazoline structural unit or enter clinical experimental stage, and the high anti-cancer activity that amido quinazoline structural unit shows and highly selective cause extensive concern.Although domestic, abroad utilizing the report having many documents in amido quinazoline mechanical development PTS and comprise patent documentation, but, the limitednumber of existing organic molecule class target anticancer new drug, and because the distribution in vivo in different tissues of the amino-quinazoline compound of different chemical structures and bioavailability are not quite similar, therefore, they are still undesirable to the restraining effect of dissimilar cancer cells.
Although at present report amino-quinazoline compound anticancer abnormal growth and improve and demonstrate many advantages in the selectivity of cancer cells etc., but still have a lot of unsatisfactory part.Therefore, utilize the polytropy of amido quinazoline structure, research and development amino-quinazoline PTS that is more, better effects if is significant further.
Summary of the invention
The object of the invention is to the limitednumber for existing organic molecule class targeted anticancer medicine, the shortcoming that cancer therapy effect is still undesirable, the 4-providing a class to have better antitumour activity (3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds or its pharmacy acceptable salt.
Another object of the present invention is to provide the preparation method of above-mentioned 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds or its pharmacy acceptable salt.
Another object of the present invention is to provide above-mentioned 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds or its pharmacy acceptable salt is preparing the application in cancer therapy drug.
Above-mentioned purpose of the present invention is achieved by following scheme:
A kind of 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds or its pharmacy acceptable salt, its structural formula is as shown in formula I:
（Ⅰ）
In above-mentioned formula I, R takes from-H ,-COCH 3,-COCF 3,-COCH=CHCOOH ,-COCH 2cl ,-COCCl 3,-COCH=CH 2,-COC (CH 3) 3,-COCH 2cH 3,-COCHBrCH 3in any one.
The present invention gives the title of 10 kinds of concrete structures and corresponding 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds, shown in specific as follows:
In above-mentioned formula I, during R=-H, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds called after 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline;
In above-mentioned formula I, R=-COCH 3time, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds called after 4-(3-chloro-4-methoxy anilino)-6-(3-acetamidophenyl) quinazoline;
In above-mentioned formula I, R=-COCF 3time, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds called after 4-(3-chloro-4-methoxy anilino)-6-(3-trifluoroacetyl amido phenyl) quinazoline;
In above-mentioned formula I, during R=-COCH=CHCOOH, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds called after 4-(3-chloro-4-methoxy anilino)-6-(the mono-maleic acylamino phenyl of 3-) quinazoline;
In above-mentioned formula I, R=-COCH 2during Cl, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds called after 4-(3-chloro-4-methoxy anilino)-6-(3-chloracetyl aminocarbonyl phenyl) quinazoline;
In above-mentioned formula I, R=-COCCl 3time, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds called after 4-(3-chloro-4-methoxy anilino)-6-(3-tribromo-acetyl amido phenyl) quinazoline;
In above-mentioned formula I, R=-COCH=CH 2time, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds called after 4-(3-chloro-4-methoxy anilino)-6-(3-acrylamido phenyl) quinazoline;
In above-mentioned formula I, R=-COC (CH 3) 3time, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds called after 4-(3-chloro-4-methoxy anilino)-6-(3-pivalyl aminocarbonyl phenyl) quinazoline;
In above-mentioned formula I, R=-COCH 2cH 3time, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds called after 4-(3-chloro-4-methoxy anilino)-6-(3-propionamido-phenyl) quinazoline;
In above-mentioned formula I, R=-COCHBrCH 3time, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds called after 4-(3-chloro-4-methoxy anilino)-6-(3-(2-bromine propionamido-) phenyl) quinazoline.
The present invention also provides the preparation method of 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds or its pharmacy acceptable salt, and this preparation method comprises the steps:
The preparation of step 1. 4-(3-chloro-4-methoxy anilino)-6-iodine quinazoline
With 4-chloro-6-iodine quinazoline and 3-chloro-4-methoxy aniline for raw material, in the presence of the solvent, react 1 ~ 12 hour at 40 ~ 100 DEG C, after reaction terminates, filter, precipitating solvent washing is to oyster, finally collect the oyster powder on filter paper, in 50 DEG C of vacuum-dryings, obtain 4-(3-chloro-4-methoxy anilino)-6-iodine quinazoline, its structure is as follows:
（Ⅱ）
In above-mentioned steps 1, the mol ratio of 4-chloro-6-iodine quinazoline and 3-chloro-4-methoxy aniline is 1:0.33 ~ 3.
In above-mentioned steps 1, one or more mixed solvents in solvent selected from methanol, ethanol, n-propyl alcohol, Virahol, propyl carbinol, isopropylcarbinol.
The chemical equation of above-mentioned steps 1 is as follows.
the preparation of step 2. 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline
With the 4-of step 1 gained (3-chloro-4-methoxy anilino)-6-iodine quinazoline (II) and 3-amido phenylo boric acid hydrate for raw material; under the existence of nitrogen protection, catalyzer, acid binding agent and solvent; 40 ~ 100 DEG C of reactions 6 ~ 30 hours; after reaction terminates, reaction solution is concentrated; then silica gel column chromatography separating-purifying is used; collect the component containing product; pale yellow powder is obtained except after desolventizing; in 50 DEG C of vacuum-dryings; obtain 4-of the present invention (3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline, its structural formula is as follows:
（Ⅲ）
In above-mentioned steps 2, the mol ratio of 4-(3-chloro-4-methoxy anilino)-6-iodine quinazoline and 3-amido phenylo boric acid hydrate is 1:0.33 ~ 3.
In above-mentioned steps 2, catalyzer is the mixture of triphenyl phosphorus and palladium or triphenyl phosphorus and Palladous chloride.
In above-mentioned steps 2, acid binding agent is selected from salt of wormwood, sodium carbonate, cesium carbonate, triethylamine, triethylenediamine, tetramethyl butane diamine, N, N-dimethyl benzylamine, N-ethylmorpholine, N, N-dimethyl cyclohexyl amine, N, N-methyl bicyclic is base amine, N-methylmorpholine, N, one or more mixtures in N-diethyl piperazine, N, N-lupetazin, salt of wormwood, sodium carbonate, cesium carbonate, potassium hydroxide, sodium hydroxide.
In above-mentioned steps 2, solvent is selected from water, ethanol, tetrahydrofuran (THF), methylene dichloride, trichloromethane, 1, one or more mixed solvents in 2-ethylene dichloride, glycol dimethyl ether, ethylene glycol monomethyl ether, ether, acetone, butanone, cyclohexanone, benzene, toluene, dioxane, DMF, pyridine, ethyl acetate.
In above-mentioned steps 2, the moving phase of silica gel column chromatography is selected from one or more mixed solvents in ethyl acetate, normal hexane, cyclohexane, sherwood oil, methyl alcohol, ethanol, methylene dichloride, trichloromethane, ether, acetone, butanone.
The chemical equation of above-mentioned steps 2 is as follows.
the preparation of step 3. 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline derivant
With the 4-of step 2 gained (3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline (III) and acid anhydrides, a kind of compound in acyl chlorides or carboxylic acid (being called for short R-C (O)-X) is raw material, in nitrogen protection, under the existence of acid binding agent and solvent, react 2 ~ 24 hours at-5 DEG C ~ 100 DEG C, after reaction terminates, reaction solution is concentrated, then silica gel column chromatography separating-purifying is used, collect the component containing product, faint yellow or yellow powder is obtained except after desolventizing, in 50 DEG C of vacuum-dryings, obtain 4-of the present invention (3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline derivant, its molecular structural formula is as shown in formula I.
In above-mentioned steps 3, the mol ratio of a kind of compound in 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline and acid anhydrides, acyl chlorides or carboxylic acid (being called for short R-C (O)-X) is 1:0.25 ~ 4.
In above-mentioned steps 3, acid binding agent is selected from triethylamine, triethylenediamine, tetramethyl butane diamine, N, N-dimethyl benzylamine, N-ethylmorpholine, N, N-dimethyl cyclohexyl amine, N, N-methyl bicyclic is base amine, N-methylmorpholine, N, one or more mixtures in N-diethyl piperazine, N, N-lupetazin, salt of wormwood, sodium carbonate, cesium carbonate, potassium hydroxide, sodium hydroxide.
In above-mentioned steps 3, one or more mixed solvents in solvent selected from ethanol, tetrahydrofuran (THF), methylene dichloride, chloroform, glycol dimethyl ether, ethylene glycol monomethyl ether, ether, acetone, toluene, dioxane, DMF, ethyl acetate.
In above-mentioned steps 3, the moving phase of silica gel column chromatography is selected from one or more mixed solvents in ethyl acetate, normal hexane, cyclohexane, sherwood oil, methyl alcohol, ethanol, methylene dichloride, trichloromethane, ether, acetone, butanone.
The chemical equation of above-mentioned steps 3 is as follows.
4-of the present invention (3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds or its pharmacy acceptable salt, described in it, pharmaceutically acceptable inorganic salt or organic salt comprise hydrochloride, vitriol, phosphoric acid salt, metilsulfate, sulfonate, formate, acetate, malate or lactic acid salt.
4-of the present invention (3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds or its pharmacy acceptable salt have good antitumor action through analysis of experiments, can separately for the preparation of antitumor drug when embody rule, or form composition with pharmaceutically acceptable carrier and prepare antitumor drug, as formed composition for oral administration or parenteral administration composition with pharmaceutically acceptable carrier.
Compared with prior art, the present invention has following beneficial effect:
The remarkable advantage of 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds prepared by the present invention has more significant restraining effect to the growth of Adenocarcinoma of lung cell line A549, hepatoma cell strain Bel-7402 and stomach cancer cell line SGC7901 tri-kinds of cancer cells, therefore, 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds that prepared by the present invention has the potential of the PTS being developed to treatment lung cancer, liver cancer and cancer of the stomach.
Embodiment
Below in conjunction with specific embodiment the present invention done and describe further, but specific embodiment does not do any restriction to the present invention.
embodiment 1 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compound
The preparation method of the present embodiment 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compound comprises the steps:
The preparation of step 1. 4-(3-chloro-4-methoxy anilino)-6-iodine quinazoline
With reflux condensing tube, in the 250ml there-necked flask of thermometer, add 4.00g(13.8 mmol successively) 4-chloro-6-iodine quinazoline, 6.51g(41.4 mmol) 3-chloro-4-methoxy aniline and 150ml Virahol, under agitation, react 1 hour at 100 DEG C, period monitors level of response with thin-layer chromatography, after reaction terminates, filter, precipitation methanol wash, until precipitation is in oyster, finally precipitation is placed in 50 DEG C of vacuum drying ovens dry, obtain oyster powder and be 4-(3-chloro-4-methoxy anilino)-6-iodine quinazoline, heavy 4.64g, productive rate 82%.Its structural formula as shown in formula II, its m.p. 243.6 DEG C; 1h-NMR(400 MHz, DMSO): δ 11.83(s, 1H), δ 9.40(s, 1H), δ 8.94(s, 1H), δ 8.35(d, 1H), δ 7.87(d, 1H), δ 7.78(d, 1H), δ 7.68(dd, 1H), δ 7.25(d, 1H), δ 3.89(s, 3H); ESI-MS m/e:414.5([M+1] +); Ultimate analysis: theoretical value C 43.77%, H 2.69%, N 10.21%, test value C 43.37%, H 2.76%, N 10.48%.
The preparation of step 2. 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline
With reflux condensing tube, in the 150ml there-necked flask of thermometer, add 0.5000g (1.215 mmol) 4-(3-chloro-4-methoxy anilino)-6-iodine quinazoline (II) successively, 0.5658g (3.645 mmol) 3-amino-benzene boric acid hydrate, the mixture of 0.0195g triphenyl phosphorus and palladium, 0.1458g sodium hydroxide and 100ml volume ratio are the tetrahydrofuran (THF)/water mixed solvent of 2/1, under agitation, react 30 hours at 40 DEG C, period monitors level of response with thin-layer chromatography, after reaction terminates, concentration of reaction solution, then separating-purifying is carried out with silica gel column chromatography, moving phase is the ethyl acetate/hexanaphthene mixed solvent of volume ratio 7/3.Collect the component containing product, obtain yellow powder after removing mixed solvent, in 50 DEG C of vacuum-dryings, obtain 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline, heavy 0.2745g, productive rate 60%.Its structural formula as shown in formula III, its m.p. 267.3 DEG C; 1h-NMR(400 MHz, DMSO): δ 9.92(s, 1H), δ 8.73(s, 1H), δ 8.59(s, 1H), δ 8.04(d, 2H), δ 7.87(d, 1H), δ 7.81(dd, 2H), δ 7.20(t, 2H), δ 7.00(d, 2H), δ 6.66(d, 1H), δ 5.25(s, 2H), δ 3.88(s, 3H); ESI-MS m/e:376.9([M+1] +); Ultimate analysis: theoretical value C 66.93%, H 4.55%, N 14.87%, test value C 66.38%, H 4.76%, N 14.36%.
embodiment 2 4-(3-chloro-4-methoxy anilino)-6-(3-acetamidophenyl) quinazoline compound
The preparation method of the present embodiment 4-(3-chloro-4-methoxy anilino)-6-(3-acetamidophenyl) quinazoline compound comprises the steps:
The preparation of step 1. 4-(3-chloro-4-methoxy anilino)-6-iodine quinazoline
With reflux condensing tube, in the 250ml there-necked flask of thermometer, add 12.00g(41.4mmol successively) 4-chloro-6-iodine quinazoline, 2.17g(13.8 mmol) 3-chloro-4-methoxy aniline and 150ml methyl alcohol, under agitation, react 12 hours at 40 DEG C, period monitors level of response with thin-layer chromatography, after reaction terminates, filter, precipitation methanol wash, until precipitation is in oyster, finally precipitation is placed in 50 DEG C of vacuum drying ovens dry, obtain oyster powder and be 4-(3-chloro-4-methoxy anilino)-6-iodine quinazoline, heavy 4.36g, productive rate 77%, its structural formula is as shown in formula II.
The preparation of step 2. 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline
With reflux condensing tube, in the 150ml there-necked flask of thermometer, add 1.5000g(3.645 mmol successively) 4-(3-chloro-4-methoxy anilino)-6-iodine quinazoline (II), 0.1886g(1.215 mmol) 3-amino-benzene boric acid hydrate, the mixture of 0.0165g triphenyl phosphorus and Palladous chloride, 0.1363g triethylenediamine and 100ml volume ratio are the cyclohexanone/water mixed solvent of 2/1, under agitation, react 6 hours at 100 DEG C, period monitors level of response with thin-layer chromatography, after reaction terminates, concentration of reaction solution, then separating-purifying is carried out with silica gel column chromatography, moving phase is the butanone/sherwood oil mixed solvent of volume ratio 8/2.Collect containing product component, after removing mixed solvent, obtain yellow powder, in 50 DEG C of vacuum-dryings, obtain 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline, heavy 0.2928g, productive rate 64%, its structural formula is as shown in formula III.
The preparation of step 3. 4-(3-chloro-4-methoxy anilino)-6-(3-acetamidophenyl) quinazoline
With reflux condensing tube, in the 150ml there-necked flask of thermometer, add 0.5000g(1.33 mmol successively) 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline (III), 0.5426g(5.32mmol) diacetyl oxide, 0.5255g triethylenediamine and 100ml dioxane, under agitation, react 2 hours at 100 DEG C, period monitors level of response with thin-layer chromatography, after reaction terminates, concentration of reaction solution, then separating-purifying is carried out with silica gel column chromatography, moving phase is the trichloromethane/normal hexane mixed solvent of volume ratio 9/1.Collect the component containing product, obtain yellow powder after removing mixed solvent, in 50 DEG C of vacuum-dryings, obtain 4-(3-chloro-4-methoxy anilino)-6-(3-acetamidophenyl) quinazoline, heavy 0.4785g, productive rate 86%.Its structural formula is as shown in formula IV.
（Ⅳ）
The m.p. 271.6 DEG C of the present embodiment 4-(3-chloro-4-methoxy anilino)-6-(3-acetamidophenyl) quinazoline; 1h-NMR(400 MHz, DMSO): δ 10.11(s, 1H), δ 9.94(s, 1H), δ 8.77(s, 1H), δ 8.60(s, 1H), δ 8.06(t, 1H), δ 8.01(s, 2H), δ 7.88(d, 1H), δ 7.77(d, 1H), δ 7.65(d, 1H), δ 7.59 ~ 7.32(m, 2H), δ 7.21(d, 1H), δ 3.88(s, 3H), δ 2.09(s, 3H); ESI-MS m/e:418.6([M+1]+); Ultimate analysis: molecular formula is C 23h 19clN 4o 2, theoretical value C 63.23%, H 4.84%, N 12.82%, test value C 63.02%, H 4.84%, N 11.98%, calculating molecular formula is thus C 23h 19clN 4o 2h 2o.
embodiment 3 4-(3-chloro-4-methoxy anilino)-6-(3-trifluoroacetyl amido phenyl) quinazoline compound
The preparation method of the present embodiment 4-(3-chloro-4-methoxy anilino)-6-(3-trifluoroacetyl amido phenyl) quinazoline compound comprises the steps:
The preparation of step 1. 4-(3-chloro-4-methoxy anilino)-6-iodine quinazoline
With reflux condensing tube, in the 250ml there-necked flask of thermometer, add 4.00g(13.8 mmol successively) 4-chloro-6-iodine quinazoline, 3.26g(20.7 mmol) 3-chloro-4-methoxy aniline and 150ml propyl carbinol, under agitation, react 8 hours at 60 DEG C, period monitors level of response with thin-layer chromatography, after reaction terminates, filter, precipitation propyl carbinol washs, until precipitation is in oyster, finally precipitation is placed in 50 DEG C of vacuum drying ovens dry, obtain oyster powder and be 4-(3-chloro-4-methoxy anilino)-6-iodine quinazoline, heavy 4.51g, productive rate 80%, its structural formula is as shown in formula II.
The preparation of step 2. 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline
With reflux condensing tube, in the 150ml there-necked flask of thermometer, add 0.5000g(1.215 mmol successively) 4-(3-chloro-4-methoxy anilino)-6-iodine quinazoline (II), 0.2829g(1.823 mmol) 3-amino-benzene boric acid hydrate, the mixture of 0.0165g triphenyl phosphorus and Palladous chloride, the volume ratio of 0.2454g triethylamine and 100ml is the glycol dimethyl ether/water mixed solvent of 2/1, under agitation, react 24 hours at 60 DEG C, period monitors level of response with thin-layer chromatography, after reaction terminates, concentration of reaction solution, then separating-purifying is carried out with silica gel column chromatography, moving phase is the butanone/normal hexane mixed solvent of volume ratio 8/2.Collect the component containing product, after removing mixed solvent, obtain yellow powder, in 50 DEG C of vacuum-dryings, obtain 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline, heavy 0.2836g, productive rate 62%, its structural formula is as shown in formula III.
The preparation of step 3. 4-(3-chloro-4-methoxy anilino)-6-(3-trifluoroacetyl amido phenyl) quinazoline
With in the 150ml there-necked flask of reflux condensing tube, thermometer, add 2.0000g(5.32mmol successively) 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline, 0.1762g(1.33 mmol) trifluoroacetyl chloride, 0.1343g triethylamine and 100ml ethyl acetate, under agitation, react 24 hours at-5 DEG C, period monitors level of response with thin-layer chromatography, after reaction terminates, concentration of reaction solution, then carry out separating-purifying with silica gel column chromatography, moving phase is the methylene dichloride/sherwood oil mixed solvent of volume ratio 9/1.Collect the component containing product, obtain deep yellow powder after removing mixed solvent, in 50 DEG C of vacuum-dryings, obtain 4-(3-chloro-4-methoxy anilino)-6-(3-trifluoroacetyl amido phenyl) quinazoline, heavy 0.5649g, productive rate 90%.Its structural formula is such as formula shown in (V).
（Ⅴ）
The m.p. 274.5 DEG C of the present embodiment 4-(3-chloro-4-methoxy anilino)-6-(3-trifluoroacetyl amido phenyl) quinazoline; 1h-NMR(400 MHz, DMSO): δ 11.44(s, 1H), δ 9.94(s, 1H), δ 8.80(s, 1H), δ 8.61(s, 1H), δ 8.18 ~ 8.04(m, 2H), δ 8.00(d, 1H), δ 7.89(d, 1H), δ 7.76(d, 3H), δ 7.62(t, 1H), δ 7.22(d, 1H), δ 3.89(s, 3H); ESI-MS m/e:472.5([M+1] +); Ultimate analysis: molecular formula is C 23h 16clF 3n 4o 2, theoretical value C 56.28%, H 3.70%, N 11.61%, test value C 59.30%, H 4.07%, N 10.90%, calculating molecular formula is thus C 23h 16clF 3n 4o 2h 2o.
embodiment 4 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds or its pharmacy acceptable salt are to the restraining effect of cancer cells
The present embodiment adopts lung cancer cell types, hepatoma cell strain Bel-7402 and stomach cancer cell line SGC7901 as experimental subjects.With 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline, 4-(3-chloro-4-methoxy anilino)-6-(3-acetamidophenyl) quinazoline, 4-(3-chloro-4-methoxy anilino)-6-(3-trifluoroacetyl amido phenyl) quinazoline, 4-(3-chloro-4-methoxy anilino)-6-(the mono-maleic acylamino phenyl of 3-) quinazoline, 4-(3-chloro-4-methoxy anilino)-6-(3-chloracetyl aminocarbonyl phenyl) quinazoline, 4-(3-chloro-4-methoxy anilino)-6-(3-tribromo-acetyl amido phenyl) quinazoline, 4-(3-chloro-4-methoxy anilino)-6-(3-acrylamido phenyl) quinazoline, 4-(3-chloro-4-methoxy anilino)-6-(3-pivalyl aminocarbonyl phenyl) quinazoline, 4-(3-chloro-4-methoxy anilino)-6-(3-propionamido-phenyl) quinazoline, 4-(3-chloro-4-methoxy anilino)-6-(3-(2-bromine propionamido-) phenyl) quinazoline is Experimental agents, 4-of the present invention (3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds carries out experimental study to the restraining effect of cancer cells, concrete operations are as follows.
Adopt MTT development process, the lung cancer cell types in vegetative period of taking the logarithm, hepatoma cell strain Bel-7402, stomach cancer cell line SGC7901, after 0.25% tryptic digestion, add perfect medium and trypsinase, and piping and druming is prepared into single cell suspension repeatedly.On tally after counting, be inoculated in 96 orifice plates with 5000, every hole cell.In 37 DEG C, 5%CO 2in incubator, quiescent culture makes cell attachment.Inhale after 24h and abandon original substratum, 1 time is washed with 150 μ L PBS, add the perfect medium containing 10% newborn calf serum that 100 μ L are fresh, then add Experimental agents, simultaneously using the substratum fluid apertures of not dosing as negative control, cultivate fluid apertures as zeroing hole (not containing cancer cells) only to add, after cultivating 72h respectively, sucking-off substratum and liquid, wash 1 time with PBS, adds 200 μ L substratum and 20 μ L concentration are 5mgmL -1mTT liquid, continue to cultivate 4h, then inhale the liquid abandoned in orifice plate, add 150 μ L DMSO and repeatedly blow and beat, bluish voilet crystallization is fully dissolved; Absorbance value (OD value) is measured with 490nm wavelength place with enzyme-linked immunosorbent assay instrument, cell survival rate (%)=(test group OD value/control group OD value) × 100%, cell inhibitory rate (%)=(1-test group OD value/control group OD value) × 100%.
Adopt IC 50be worth as shown in table 1 to the antitumour activity evaluation result of 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds.By the OD value measured in different time points, obtain the inhibiting rate changing conditions of different time points, draw change curve, using curve arrival that time point of plateau as optimum time point, show that the best use of time of medicine is 36h by time curve.
The IC of table 1 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds effect after 36 hours 50value
As can be seen from Table 1,4-of the present invention (3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds all demonstrates good antitumour activity to Adenocarcinoma of lung cell line A549, hepatoma cell strain Bel-7402 and stomach cancer cell line SGC7901.

Claims (9)

1. 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds or its pharmacy acceptable salt, its structural formula is as shown in formula I:
（Ⅰ）
In formula I, as R=-H, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds is 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline;
As R=-COCH 3time, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds is 4-(3-chloro-4-methoxy anilino)-6-(3-acetamidophenyl) quinazoline;
As R=-COCF 3time, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds is 4-(3-chloro-4-methoxy anilino)-6-(3-trifluoroacetyl amido phenyl) quinazoline;
As R=-COCH=CHCOOH, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds is 4-(3-chloro-4-methoxy anilino)-6-(the mono-maleic acylamino phenyl of 3-) quinazoline;
As R=-COCH 2during Cl, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds is 4-(3-chloro-4-methoxy anilino)-6-(3-chloracetyl aminocarbonyl phenyl) quinazoline;
As R=-COCCl 3time, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds is 4-(3-chloro-4-methoxy anilino)-6-(3-tribromo-acetyl amido phenyl) quinazoline;
As R=-COCH=CH 2time, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds is 4-(3-chloro-4-methoxy anilino)-6-(3-acrylamido phenyl) quinazoline;
As R=-COC (CH 3) 3time, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds is 4-(3-chloro-4-methoxy anilino)-6-(3-pivalyl aminocarbonyl phenyl) quinazoline;
As R=-COCH 2cH 3time, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds is 4-(3-chloro-4-methoxy anilino)-6-(3-propionamido-phenyl) quinazoline;
As R=-COCHBrCH 3time, this 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds is 4-(3-chloro-4-methoxy anilino)-6-(3-(2-bromine propionamido-) phenyl) quinazoline.
2. 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds or its pharmacy acceptable salt according to claim 1, it is characterized in that, described pharmacy acceptable salt is hydrochloride, vitriol, phosphoric acid salt, metilsulfate, sulfonate, formate, acetate, malate or lactic acid salt.
3. the preparation method of 4-described in claim 1 (3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds or its pharmacy acceptable salt, is characterized in that this preparation method comprises the steps:
The preparation of step 1. 4-(3-chloro-4-methoxy anilino)-6-iodine quinazoline
With 4-chloro-6-iodine quinazoline and 3-chloro-4-methoxy aniline for raw material, in the presence of the solvent, react 1 ~ 12 hour at 40 ~ 100 DEG C, after reaction terminates, filter, precipitating solvent washing is to oyster, finally collect the oyster powder on filter paper, in 50 DEG C of vacuum-dryings, obtain 4-(3-chloro-4-methoxy anilino)-6-iodine quinazoline, its structure is as follows:
；
（Ⅱ）
The preparation of step 2. 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline
With the 4-of step 1 gained (3-chloro-4-methoxy anilino)-6-iodine quinazoline (II) and 3-amido phenylo boric acid hydrate for raw material; under the existence of nitrogen protection, catalyzer, acid binding agent and solvent; 40 ~ 100 DEG C of reactions 6 ~ 30 hours; after reaction terminates, reaction solution is concentrated; then silica gel column chromatography separating-purifying is used; collect the component containing product; pale yellow powder is obtained except after desolventizing; in 50 DEG C of vacuum-dryings; obtain 4-of the present invention (3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline, its structural formula is as follows:
；
（Ⅲ）
The preparation of step 3. 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline derivant
With the 4-of step 2 gained (3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline (III) and acid anhydrides, a kind of compound in acyl chlorides or carboxylic acid is raw material, in nitrogen protection, under the existence of acid binding agent and solvent, react 2 ~ 24 hours at-5 DEG C ~ 100 DEG C, after reaction terminates, reaction solution is concentrated, then silica gel column chromatography separating-purifying is used, collect the component containing product, faint yellow or yellow powder is obtained except after desolventizing, in 50 DEG C of vacuum-dryings, obtain 4-of the present invention (3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline derivant, its molecular structure is as shown in formula I.
4. preparation method according to claim 3, it is characterized in that in described step 1, the mol ratio of 4-chloro-6-iodine quinazoline and 3-chloro-4-methoxy aniline is 1:0.33 ~ 3; In described step 2, the mol ratio of 4-(3-chloro-4-methoxy anilino)-6-iodine quinazoline and 3-amido phenylo boric acid hydrate is 1:0.33 ~ 3; In described step 3, the mol ratio of a kind of compound in 4-(3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline and acid anhydrides, acyl chlorides or carboxylic acid is 1:0.25 ~ 4.
5. preparation method according to claim 3, is characterized in that in described step 1, one or more mixed solvents in solvent selected from methanol, ethanol, n-propyl alcohol, Virahol, propyl carbinol, isopropylcarbinol.
6. preparation method according to claim 3, it is characterized in that in described step 2, catalyzer is the mixture of triphenyl phosphorus and palladium or triphenyl phosphorus and Palladous chloride; Acid binding agent is selected from salt of wormwood, sodium carbonate, cesium carbonate, triethylamine, triethylenediamine, tetramethyl butane diamine, N, N-dimethyl benzylamine, N-ethylmorpholine, N, N-dimethyl cyclohexyl amine, N, N-methyl bicyclic is base amine, N-methylmorpholine, N, one or more mixtures in N-diethyl piperazine, N, N-lupetazin, salt of wormwood, sodium carbonate, cesium carbonate, potassium hydroxide, sodium hydroxide; Solvent is selected from water, ethanol, tetrahydrofuran (THF), methylene dichloride, trichloromethane, 1, one or more mixed solvents in 2-ethylene dichloride, glycol dimethyl ether, ethylene glycol monomethyl ether, ether, acetone, butanone, cyclohexanone, benzene, toluene, dioxane, DMF, pyridine, ethyl acetate.
7. preparation method according to claim 3, it is characterized in that in described step 3, acid binding agent is selected from triethylamine, triethylenediamine, tetramethyl butane diamine, N, N-dimethyl benzylamine, N-ethylmorpholine, N, N-dimethyl cyclohexyl amine, N, N-methyl bicyclic one or more mixtures in base amine, N-methylmorpholine, N, N-diethyl piperazine, N, N-lupetazin, salt of wormwood, sodium carbonate, cesium carbonate, potassium hydroxide, sodium hydroxide; One or more mixed solvents in solvent selected from ethanol, tetrahydrofuran (THF), methylene dichloride, chloroform, glycol dimethyl ether, ethylene glycol monomethyl ether, ether, acetone, toluene, dioxane, DMF, ethyl acetate.
8. preparation method according to claim 3, it is characterized in that in described step 2 and 3, the moving phase of silica gel column chromatography is selected from one or more mixed solvents in ethyl acetate, normal hexane, cyclohexane, sherwood oil, methyl alcohol, ethanol, methylene dichloride, trichloromethane, ether, acetone, butanone.
9. 4-described in claim 1 (3-chloro-4-methoxy anilino)-6-(3-aminocarbonyl phenyl) quinazoline compounds or its pharmacy acceptable salt are preparing the application in antitumor drug.
CN201210194142.7A 2012-06-13 2012-06-13 4-(3-chloro-4-methoxylanilino)-6-(3-amidophenyl)quinazoline compound or pharmaceutically-acceptable salt thereof and preparation methods and applications thereof Expired - Fee Related CN102702116B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210194142.7A CN102702116B (en) 2012-06-13 2012-06-13 4-(3-chloro-4-methoxylanilino)-6-(3-amidophenyl)quinazoline compound or pharmaceutically-acceptable salt thereof and preparation methods and applications thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210194142.7A CN102702116B (en) 2012-06-13 2012-06-13 4-(3-chloro-4-methoxylanilino)-6-(3-amidophenyl)quinazoline compound or pharmaceutically-acceptable salt thereof and preparation methods and applications thereof

Publications (2)

Publication Number Publication Date
CN102702116A CN102702116A (en) 2012-10-03
CN102702116B true CN102702116B (en) 2014-12-31

Family

ID=46895225

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210194142.7A Expired - Fee Related CN102702116B (en) 2012-06-13 2012-06-13 4-(3-chloro-4-methoxylanilino)-6-(3-amidophenyl)quinazoline compound or pharmaceutically-acceptable salt thereof and preparation methods and applications thereof

Country Status (1)

Country Link
CN (1) CN102702116B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103864750A (en) * 2014-03-11 2014-06-18 清华大学 Derivative of N-biphenyl dichloroacetamide as well as preparation method and applications thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1211240A (en) * 1996-02-14 1999-03-17 曾尼卡有限公司 Quinazoline derivatives as antitumor agents
WO2005105094A2 (en) * 2004-04-16 2005-11-10 Smithkline Beecham Corporation Cancer treatment method
CN1950345A (en) * 2004-04-28 2007-04-18 阿罗治疗有限公司 Morpholinylanilinoquinazoline derivatives for use as antiviral agents
CN101003514A (en) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 Derivative of quinazoline, preparation method and usage
US20080194557A1 (en) * 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
EP2060565A1 (en) * 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
US20090285782A1 (en) * 2006-07-20 2009-11-19 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2011082337A1 (en) * 2009-12-31 2011-07-07 Galenea Corp. Therapeutic compounds and related methods of use
WO2011116634A1 (en) * 2010-03-23 2011-09-29 Scinopharm Taiwan Ltd. Process and intermediates for preparing lapatinib
CN102321076A (en) * 2011-07-07 2012-01-18 中国科学技术大学 The preparation method of lapatinibditosylate midbody and analogue thereof
WO2012017448A2 (en) * 2010-08-03 2012-02-09 Hetero Research Foundation Salts of lapatinib

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1211240A (en) * 1996-02-14 1999-03-17 曾尼卡有限公司 Quinazoline derivatives as antitumor agents
WO2005105094A2 (en) * 2004-04-16 2005-11-10 Smithkline Beecham Corporation Cancer treatment method
CN1950345A (en) * 2004-04-28 2007-04-18 阿罗治疗有限公司 Morpholinylanilinoquinazoline derivatives for use as antiviral agents
CN101003514A (en) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 Derivative of quinazoline, preparation method and usage
US20090285782A1 (en) * 2006-07-20 2009-11-19 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US20080194557A1 (en) * 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
EP2060565A1 (en) * 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
WO2009063054A1 (en) * 2007-11-16 2009-05-22 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
WO2011082337A1 (en) * 2009-12-31 2011-07-07 Galenea Corp. Therapeutic compounds and related methods of use
WO2011116634A1 (en) * 2010-03-23 2011-09-29 Scinopharm Taiwan Ltd. Process and intermediates for preparing lapatinib
WO2012017448A2 (en) * 2010-08-03 2012-02-09 Hetero Research Foundation Salts of lapatinib
CN102321076A (en) * 2011-07-07 2012-01-18 中国科学技术大学 The preparation method of lapatinibditosylate midbody and analogue thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺盐酸盐的合成;王武伟,等;《化工中间体》;20081115(第11期);第28-30页 *
Novel Chimeric Histone Deacetylase Inhibitor s: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR ), Human Epidermal Growth Factor Receptor 2 (HER2),and Histone Deacetylase Activity;Siavosh Mahboobi,等;《J. Med. Chem.》;20101116;第53卷(第24期);第8546-8555页 *
埃罗替尼衍生物的合成及抗肿瘤活性;徐浩,等;《中国药科大学学报》;20081225;第39卷(第06期);第487-490页 *
盐酸埃洛替尼的合成;李铭东,等;《中国医药工业杂志》;20070410;第38卷(第04期);第257-259页 *
金波,等.吉非替尼的合成.《中国药科大学学报》.2005,第36卷(第01期),第92-94页. *

Also Published As

Publication number Publication date
CN102702116A (en) 2012-10-03

Similar Documents

Publication Publication Date Title
CN102206172B (en) Substituted diaryl compound and preparation method and antiviral application thereof
CN102295635B (en) Antitumor medicament tetralin amide compounds and pharmaceutically acceptable salts thereof as well as preparation method and application of antitumor medicament tetralin amide compounds
CN105399757A (en) Acid-sensitive camptothecin-site 20 norcantharidate derivative and antineoplastic application thereof
CN101323591A (en) 5- or 6-substited naphthoyl imines compounds and antineoplastic application
JP2021514967A (en) Crystal type, salt type and method for producing the pyridinoimidazole compound
WO2013178021A1 (en) Pyrrole [2, 1-f][1, 2, 4] triazine derivative and antitumor effect thereof
CN111808117B (en) Artemisinin-anilino quinazoline D-type derivative, and pharmaceutical composition and application thereof
CN110922415B (en) Synthesis and application of novel anti-tumor active compound
CN102702116B (en) 4-(3-chloro-4-methoxylanilino)-6-(3-amidophenyl)quinazoline compound or pharmaceutically-acceptable salt thereof and preparation methods and applications thereof
CN105646546A (en) Acid-sensitive camptothecin-20-position ester derivative and antineoplastic application thereof
CN103435560B (en) Synthesis and application of aceanthrylene [1,2-b] quinoxaline derivative with flexible side chain
CN102617478B (en) Synthesis of benzimidazole, oxazole and thiazole derivatives and application thereof
CN103012394B (en) Rhodanine derivative and preparation method thereof
CN102924387B (en) 4-(3-chloro-4-methoxyanilino)-6-(3,4-substituted phenyl)quinazoline and salts thereof, preparation method and applications
CN102863438A (en) N-(4-(4-(pyridine-2-radical) piperazine-1-radical) pyrimidine-2-radical) amide and salt and preparation method and application thereof
CN101497608B (en) HIV protease inhibitor derivative, preparation thereof and use in antineoplastic medicament preparation
CN105130896B (en) The naphthalimide derivative of a kind of substituent containing thiocarbamide, its preparation method and application
CN104250250A (en) 4-aromatic aminopyrimidine compound and anti-tumor use thereof
CN102702179A (en) 4-(3-chloro-4-methoxylanilino)-6-(furan-2-radical)quinazoline compound or pharmaceutically-acceptable salt thereof and preparation methods and applications thereof
CN109369634B (en) Preparation method and application of 2-methoxynicotinamide derivative with antitumor activity
CN111670191B (en) Crystal form of pyridone derivative, preparation method and application
CN112225737B (en) Compound with HDAC (Histone deacetylase) inhibitory activity, preparation method, composition and application
CN106543155B (en) Chalcone and flavonoid derivative as aurora kinase inhibitor
CN110183471B (en) Piperazine derivative, preparation method and application
CN109438482B (en) Bis-fluoroquinolone oxadiazole urea derivative containing rufloxacin and preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141231

Termination date: 20210613